奈玛特韦/利托那韦在重度和中度COVID-19合并严重肾损伤患者中的安全性、药代动力学及剂量推荐
EPIC-SRI研究纳入15例严重肾损伤COVID-19患者(3例无需血透,12例间歇血透),接受奈玛特韦/利托那韦300/100 mg第1天,随后150/100 mg每日一次第2-5天。未报告治疗相关不良事件,群体药代动力学模拟显示该方案暴露与正常至中度肾功能患者获批剂量相似,SARS-CoV-2 RNA水平显著下降。
要点
- 严重肾损伤患者采用奈玛特韦/利托那韦300/100 mg第1天、150/100 mg每日一次第2-5天方案耐受性良好。
- 间歇血透队列奈玛特韦每日给药Cmax、Ctrough和AUC0-24几何均值分别为3280 ng/mL、2188 ng/mL和65700 ng*h/mL。
- 血透清除率和经血透清除比例几何均值分别为30.5 mL/min和6.9%。
核心结论
- 研究方案在COVID-19合并严重肾损伤患者中耐受性良好,达到并维持足够暴露,适用于该人群。
研究设计与样本
- 1期EPIC-SRI研究纳入15例严重肾损伤COVID-19患者,其中3例不需血透、12例需间歇血透。
主要发现
- 未报告治疗相关不良事件。
- 间歇血透队列奈玛特韦每日给药Cmax几何均值3280 ng/mL(CV 48%),Ctrough 2188 ng/mL(CV 81%),AUC0-24 65700 ng*h/mL(CV 59%)。
- 奈玛特韦血透清除率几何均值30.5 mL/min(CV 35%),经血透清除比例6.9%(CV 138%)。
- 群体药代动力学模拟显示该方案暴露与正常至中度肾功能患者获批剂量相似。
- 两个队列SARS-CoV-2 RNA水平均显著下降。
关键数值与推荐
- 奈玛特韦/利托那韦第1天300/100 mg,第2-5天150/100 mg每日一次。
临床怎么用
- 严重肾损伤COVID-19患者可按研究方案使用奈玛特韦/利托那韦300/100 mg第1天、150/100 mg每日一次第2-5天。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with severe renal impairment and COVID-19 are at high risk for severe disease and death. Nirmatrelvir/ritonavir, an antiviral therapy for COVID-19, is eliminated by renal excretion and can accumulate in patients with severe renal impairment. The phase 1 Evaluation of Protease Inhibition for COVID-19 in Patients with Severe Renal Impairment (EPIC-SRI) study evaluated the safety and pharmacokinetics of nirmatrelvir/ritonavir for this population. Fifteen participants (3 not requiring hemodialysis, 12 requiring intermittent hemodialysis) received oral nirmatrelvir/ritonavir 300/100 mg on Day 1, followed by nirmatrelvir/ritonavir 150/100 mg once daily on Days 2-5. No treatment-related adverse events were reported. Geometric mean (coefficient of variation) maximum plasma concentration, plasma trough concentration, and area under the concentration-time curve from 0 to 24 hours for daily dosing of nirmatrelvir for participants from the Intermittent Hemodialysis Cohort were 3280 ng/mL (48%), 2188 ng/mL (81%), and 65,700 ng*h/mL (59%), respectively. Geometric mean (coefficient of variation) nirmatrelvir hemodialysis clearance and fraction removed from the body by hemodialysis were 30.5 mL/min (35%) and 6.9% (138%), respectively. Population pharmacokinetic modeling demonstrated that simulated distributions of nirmatrelvir maximum plasma concentration, minimum trough concentration, and area under the concentration-time curve from 0 to 24 hours for daily dosing at the studied regimen were similar to those for virtual subjects with normal to moderate renal function receiving the approved dose of nirmatrelvir/ritonavir. SARS-CoV-2 RNA levels were substantially reduced across both cohorts. Findings suggest that the studied regimen is well tolerated, achieves and maintains adequate exposure, and is suitable for patients with COVID-19 and severe renal impairment. NCT05487040.
引用
- Gerhart J, Bramson CR, Goulding M, et al. Safety, Pharmacokinetics, and Dose Recommendations for Nirmatrelvir/Ritonavir in Individuals with Mild to Moderate COVID-19 and Severe Renal Impairment. Clin Pharmacol Ther. 2026. PMID: 41823072. doi:10.1002/cpt.70252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。